|
|
 |
|
Viewing report
|
|
|
|
Molecular Imaging: A Market Coming of Age
Espicom Business Intelligence Ltd, Aug 2011, Pages: 290
Critical review of the market conditions, trends and challenges
Unique market forecasts to 2015 by major sector
Comprehensive and detailed competitive analysis of 75 leading players
The early vision for molecular imaging (MI) was that it would revolutionise clinical diagnostics and pharmaceutical research, allowing disease to be explored and identified with greater accuracy and long before physical symptoms were experienced. But economic recession and technical challenges have taken their toll on the speed at which that vision has become reality, until now. While for many years MI delivered more promise than profits, the signs are that new products, applications and increasing clinical/health payer acceptance will see the market accelerate in the medium term to achieve global sales of US$6 billion by 2015.
Strong fundamentals are driving growth
Despite cost pressures from reduced capital spending and lower reimbursement for some procedures, the MI market fundamentals remain solid and there are strong opportunities for growth within the MI industry. The increasing incidence of cancer, cardiovascular and neurological diseases means that demand for faster and more accurate diagnosis, as well as drug development and pre-clinical study efforts, will continue to accelerate in the coming years. In addition, imaging technologies will become more widely adopted as clinical evidence is established as to their benefits, and new technological innovations continue to be brought to market, particularly related to the MI of cancer and neurological diseases. In addition, the current lack of penetration for nuclear and molecular imaging in emerging economies such as China, India and Brazil is driving demand in these regions, where new nuclear imaging facilities are being set up and lower-cost systems are in demand.
Corporate manoeuvres
The industry is still developing but already companies in the medical diagnostic imaging equipment business such as Philips, Siemens and GE, and in the radiopharmaceutical and contrast agent market such as GE, Bracco, Covidien, Bayer and Lantheus Medical Imaging are taking leading positions. And opportunities for big Pharma are not being missed, with both Eli Lilly and AstraZeneca actively involved. As the market develops, expect more consolidation in the tussle for dominance.
This new report provides unique 5-year market forecasts
Molecular imaging is still a developing sector and the question is often asked what it will be worth commercially. For the first time, this report provides a 5-year evaluation of the market's prospects and provides year-by year growth for key sectors:
- Nuclear Imaging
- Pre-Clinical Imaging Systems
- Molecular Imaging End-Use Products Market
- Radiopharmaceuticals
This report easily answers key business questions such as:
- Which sector of the molecular imaging market is expected to achieve global sales of US$3.5 billion in 2015?
- What steps are being taken to ensure availability of the key istope Mo-99?
- How is Gallium-68 being used to better understand cancer cell migration?
- What advantages does PET have over other imaging technologies?
- What challenges must be overcome to meet growing demand in emerging markets and how is this influencing developers?
- Which European company is developing nanoprobes which identify the expression of the HER2 protein and with whom is it collaborating?
- Which US company was granted a European patent in March 2011 for its contrast agent used in the diagnosis of deep vein thrombosis?
- Now approved in the US and EU, does Digirad's portable nuclear system mark a move to distributed MI technologies?
- Only one company offers a full suite of MI product; is this a competitive advantage and does it represent an opportunity for further entrants to provide whole-market service?
A complete analysis packed with market analysis, sector forecasts to 2015 and detailed company evaluations
This report delivers the most complete and critical appraisal of the market, products and companies operating in this fast-growing health sector
To view the reports full table of contents, please see the sample provided
Product samples
A sample for this product is available. Please Login/Register to download this sample.
|
|
|
|
